Patrick Harrington, PhD, is a Senior Clinical Virology Reviewer at the FDA Center for Drug Evaluation and Research, Division of Antiviral Products. At the FDA, Dr. Harrington reviews nonclinical and clinical virology data and clinical trial protocols for antiviral drugs. He is also actively involved in the establishment of FDA policies and guidance on HCV drug development. Prior to joining the FDA in 2008, Dr. Harrington was a Research Assistant Professor in the Department of Microbiology and Immunology at the University of North Carolina (UNC) at Chapel Hill. Dr. Harrington also received his Ph.D. and postdoctoral training at UNC-Chapel Hill. He has research and regulatory review experience with a variety of viruses, including HCV, HIV/SIV, noroviruses, alphaviruses and coronaviruses.